Jochen Wöhrle

Prof. Jochen Wöhrle

Department of Internal Medicine II, Cardiology, University of Ulm, Ulm, Germany
orcid

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2022 in Circulation: Cardiovascular Interventions
Verified
Journal Article
Closed access
PDF file
BSBruno Scheller
Bruno Scheller
TRTuomas T. Rissanen
Tuomas T. Rissanen
AFAhmed Farah
Ahmed Farah
MOMarc-Alexander Ohlow
Marc-Alexander Ohlow
NMNorman Mangner
Norman Mangner
FIfor the BASKET-SMALL 2 Investigators
for the BASKET-SMALL 2 Investigators
Background: Patients at high-bleeding risk (HBR) undergoing percutaneous coronary intervention represent a challenging patient population. The use of drug-coated balloon (DCB) allows shorter duration of dual antiplatelet therapy compared with drug-eluting stents (DES) and reduces thrombotic risk due to the absence of a permanent implant. The present analysis aimed to investigate if the effect of DCB versus DES differed between patients with and without HBR treated with percutaneous coronary intervention in small coronary arteries. Methods: This prespecified subgroup analysis of a multicenter, randomized, noninferiority trial included 758 patients with de novo lesions in coronary vessels <3 mm and an indication for percutaneous coronary intervention, randomized to DCB (n=382) or second-generation DES (n=376). Patients were followed over 3 years for major adverse cardiac events. Results: Of the 758 patients randomized, 155 (20%) had HBR; these patients had higher mortality at 3 years (hazard ratio [95% CI], 3.09 [1.78–5.36]; P <0.001). Rates of major bleeding events were overall low but tended to be lower after DCB versus DES (1.6% versus 3.7%; P =0.064), were similar in patients with HBR (4.5% versus 3.4%) but less frequent in DCB-versus DES-treated patients without HBR (0.9% versus 3.8%). There was no difference in major adverse cardiac events between DCB and DES regardless of bleeding risk (HBR, hazard ratio: 1.16 [0.51–2.62]; P =0.719 versus non-HBR, 0.96 [0.62–1.49]; P =0.863). Conclusions: DCBs were similarly safe and effective as current-generation DES in the treatment of coronary arteries <3 mm, regardless of bleeding risk. In patients treated with DCB, there was a trend towards a reduction of severe bleeding events at 3 years. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT01574534.

1 August 2021 in JACC: Cardiovascular Interventions
Verified
Journal Article
Closed access
Jochen WöhrleJochen Wöhrle
Jochen Wöhrle
BSBruno Scheller
Bruno Scheller
JSJulia Seeger
Julia Seeger
AFAhmed Farah
Ahmed Farah
MOMarc-Alexander Ohlow
Marc-Alexander Ohlow
RJRaban V. Jeger
Raban V. Jeger

1 February 2022 in Circulation: Cardiovascular Interventions
Verified
Journal Article
Closed access
PDF file
NMNorman Mangner
Norman Mangner
AFAhmed Farah
Ahmed Farah
MOMarc-Alexander Ohlow
Marc-Alexander Ohlow
SMSven Möbius-Winkler
Sven Möbius-Winkler
DWDaniel Weilenmann
Daniel Weilenmann
FIfor the BASKET-SMALL 2 Investigators
for the BASKET-SMALL 2 Investigators
Background: Drug-coated balloons (DCBs) are an established treatment strategy for coronary artery disease. Randomized data on the application of DCBs in patients with an acute coronary syndrome (ACS) are limited. We evaluated the impact of clinical presentation (ACS versus chronic coronary syndrome) on clinical outcomes in patients undergoing DCB or drug-eluting stent (DES) treatment in a prespecified analysis of the BASKET-SMALL 2 trial (Basel Kosten Effektivitäts Trial–Drug-Coated Balloons Versus Drug-Eluting Stents in Small Vessel Interventions). Methods: BASKET-SMALL 2 randomized 758 patients with small vessel coronary artery disease to DCB or DES treatment and followed them for 3 years regarding major adverse cardiac events (cardiac death, nonfatal myocardial infarction, and target vessel revascularization). Results: Among 758 patients, 214 patients (28.2%) presented with an ACS (15 patients [7%], ST-segment–elevation myocardial infarction; 109 patients [50.9%], non–ST-segment–elevation myocardial infarction; 90 patients [42.1%], unstable angina pectoris). At 1-year follow-up, there was no significant difference in the incidence of the primary end point by randomized treatment in patients with ACS (hazard ratio, 0.50 [95% CI, 0.19–1.26] for DCB versus DES) or chronic coronary syndrome (hazard ratio, 1.29 [95% CI, 0.67–2.47] for DCB versus DES). There was no significant interaction between clinical presentation and treatment effect ( P for interaction, 0.088). For cardiac death ( P for interaction, 0.049) and nonfatal myocardial infarction ( P for interaction, 0.010), a significant interaction between clinical presentation and treatment was seen at 1 year with lower rates of these secondary end points in patients with ACS treated by DCB. At 3 years, there were similar major adverse cardiac event rates throughout groups without significant interaction between clinical presentation and treatment ( P for interaction, 0.301). All-cause mortality was higher in ACS compared with chronic coronary syndrome; however, there was no difference between DCB and DES irrespective of clinical presentation. Conclusions: In this subgroup analysis of the BASKET-SMALL 2 trial, there was no interaction between indication for percutaneous coronary intervention (acute versus chronic coronary syndrome) and treatment effect of DCB versus DES in patients with small vessel coronary artery disease. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT01574534.

22 May 2007 in Journal of Magnetic Resonance Imaging
Verified
Journal Article
Open access
PDF file
CBChristof Burgstahler
Christof Burgstahler
Jochen WöhrleJochen Wöhrle
Jochen Wöhrle
MKMatthias Kochs
Matthias Kochs
TNThorsten Nusser
Thorsten Nusser
CLChristine Löffler
Christine Löffler
NMNico Merkle
Nico Merkle
Purpose: To evaluate acute changes in atrial and ventricular parameters by the use of cardiac magnetic resonance imaging (MRI) in patients with percutaneous transcatheter atrial septal defects (ASD) closure.Materials and Methods: The study included 14 patients (six males and eight females, 45 ± 18 years) with congenital ASD. Cardiac MRI (1.5T Philips Intera CV) was performed before and within 24 hours after transcatheter ASD closure. Right atrial (RA) and left atrial (LA) dimensions, as well as right (RV) and left (LV) ventricular end‐diastolic (ED) volumes were determined. Atrial size was assessed by planimetry of the maximum RA and LA areas in a standard four‐chamber view, and ventricular volumes were calculated according to a modified Simpson's rule in short‐axis views.Results: The mean RA decreased significantly from 27.6 ± 6.4 cm2 before closure to 24.4 ± 5.6 cm2 after the procedure (P = 0.0018), whereas the LA area did not change (24.1 ± 4.7 cm2 vs. 23.8 ± 5.2 cm2, P = 0.76). The RV volumes, volume index, and ejection fraction (EF) decreased significantly from 229 ± 64 mL to 181 ± 43 mL (P < 0.001, average reduction = 19% ± 15%), from 126.0 ± 37.2 mL/m2 to 96.6 ± 28.6 mL/m2 (P < 0.0001) and from 64 ± 5% to 58% ± 7% (P = 0.01), respectively. The LV volumes and volume index remained unchanged (114 ± 25 mL vs. 118 ± 22 mL, P = 0.18, 63.5 ± 13.5 mL/m2 vs. 63.0 ± 17.4 mL/m2, P = 0.83). Left–right shunting decreased from 40% ± 15% to 9% ± 15% (P < 0.001).Conclusion: Cardiac MRI can reveal detailed information on acute changes in shunt fraction and ventricular dimensions after ASD closure. ASD closure by percutaneous transcatheter device implantation results within 24 hours in a significant reduction of shunt fraction, RA and RV sizes, and RV function, whereas LA and LV dimensions remain unchanged. J. Magn. Reson. Imaging 2007;25:1136–1140.

1 January 2001 in Cardiovascular Research
Verified
Journal Article
Closed access
MWM Wohlfrom
M Wohlfrom
JKJ Kotzerke
J Kotzerke
JKJ Kamenz
J Kamenz
MEM Eble
M Eble
BHB Hess
B Hess
MHM Höher
M Höher
Postinterventional irradiation is a new therapeutic concept in the prevention of restenosis. The liquid beta-emitter Rhenium-188 allows endovascular brachytherapy using a conventional balloon catheter without the problem of centering the radiation source. In an animal model of restenosis the feasibility and the dose dependent effect of intravascular brachytherapy with a Rhenium-188 filled balloon catheter was investigated. In 68 male New Zealand White rabbits after endothelial denudation of the right common carotid artery with a Fogarty catheter, endovascular irradiation was performed with a Rhenium-188 filled 3.0-mm balloon catheter using different dosages (0, 7.5, 15, 30, 45 and 60 Gy at the surface of the vessel). Then 4 weeks after the intervention the vessels were excised and histologically analyzed. Whereas at 7.5 Gy the intimal area (median [first quartile; third quartile]) did not differ significantly from the control (0.46 mm(2) [0.33 mm(2), 0.75 mm(2)] vs. 0.49 mm(2) [0.34 mm(2), 0.66 mm(2)]), neointimal hyperplasia was decreased significantly at 15 Gy (0.15 mm(2) [0.04 mm(2), 0.17 mm(2)]) and 30 Gy (0.07 mm(2) [0.04 mm(2), 0. 10 mm(2)]), and completely inhibited at the highest dosages (45 Gy: 0 mm(2) [0 mm(2), 0.04 mm(2)]; 60 Gy: 0 mm(2) [0 mm(2), 0.01 mm(2)]). Catheter transmitted endovascular irradiation with the liquid beta-emitter Rhenium-188 after vascular injury is feasible and effectively reduced neointimal hyperplasia in hypercholesterolemic rabbits. A significant reduction of the neointimal formation could be found already at a radiation absorbed dose of 15 Gy at the vessel surface. Following a surface dosage of 45 Gy the proliferative response to the vessel injury is almost completely abolished.

1 April 2021 in Cardiovascular Revascularization Medicine
Verified
Journal Article
Open access
RBRalf Birkemeyer
Ralf Birkemeyer
GOGöran K. Olivecrona
Göran K. Olivecrona
FHFarrel Hellig
Farrel Hellig
Jochen WöhrleJochen Wöhrle
Jochen Wöhrle
WRWolfgang Rottbauer
Wolfgang Rottbauer
NDNicolas Dumonteil
Nicolas Dumonteil
The PAST-PERF registry was initiated to collect data on the PK Papyrus covered stent, a second-generation device for the treatment of coronary artery perforations with enhanced mechanical properties, but with limited available data. Patients treated for coronary artery perforations with the PK Papyrus stent at 14 international centers were retrospectively identified. The primary effectiveness outcome was successful sealing of the perforation. The primary safety outcome was a composite of all-cause mortality, definite or probable stent thrombosis, myocardial infarction and target lesion revascularization. Among the 94 included patients, 72.3% (68/94) had Ellis type III and cavity spilling perforations. Complete sealing was achieved in 93.6% (n = 88), and no sealing could be achieved in 3.2% (n = 3, including one patient with a geographical miss and one patient in whom the device could not be implanted). Pericardiocentesis was required in 25.0% (n = 23), emergency cardiac surgery was needed in 7.6% (n = 7), acute stent thrombosis was observed in 1.1% (n = 1), and in-hospital mortality occurred in 11.7% (n = 11). The median follow-up duration was 283 (IQR:40;670) days. At 6 and 12 months, the incidence of the primary safety endpoint was 26.6% [95%CI:18.6;37.1] and 32.0% [95%CI:22.8;43.4], mortality 15.0% [95%CI:9.0;24.6] and 19.0% [95%CI:11.3;30.0], and target lesion revascularization 5.5% [95%CI:2.0;14.6] and 7.7% [95%CI:3.1;18.2]. Two definite stent thrombosis occurred, one during the procedure and one on post-procedure day 233. The registry demonstrates favorably high rates of successful stent delivery and sealing of coronary perforations using a second-generation covered stent with low target lesion revascularization and stent thrombosis rates. The PAST-PERF registry demonstrates favorably high rates of successful stent delivery and sealing of coronary perforations using a second-generation covered stent with low target lesion revascularization and stent thrombosis rates. Specifically, complete sealing was achieved in 93.6% of patients (n = 88/94), and no sealing could be achieved in 3.2% (n = 3, including one patient with a geographical miss and one patient in whom the device could not be implanted). The 12-month mortality was 19.0% [95%CI:11.3;30.0], the rate of target lesion revascularization was 7.7% [95%CI:3.1;18.2], and two definite stent thromboses occurred (one during procedure and one on post-procedure day 233).